Introduction: The Unified Dyskinesia Rating Scale (UDysRS) was developed to provide a comprehensive rating tool of dyskinesia in Parkinson’s disease (PD). Because dyskinesia therapy trials involve multicenter studies, having a scale that is validated in multiple non-English languages is pivotal to international efforts to treat dyskinesia. The aim of the present study was to organize and perform an independent validation of the UDysRS Finnish version. Methods: The UDysRS was translated into Finnish and then back-translated into English using 2 independent teams. Cognitive pretesting was conducted on the Finnish version and required modifications to the structure or wording of the translation. The final Finnish version was administered to 250 PD patients whose native language is Finnish. The data were analyzed to assess the confirmatory factor structure to the Spanish UDysRS (the reference standard). Secondary analyses included an exploratory factor analysis (EFA), independent of the reference standard. Results: The comparative fit index (CFI), in comparison with the reference standard factor structure, was 0.963 for Finnish. In the EFA, where variability from sample to sample is expected, isolated item differences of factor structure were found between the Finnish and Reference Standard versions of the UDysRS. These subtle differences may relate to differences in sample composition or variations in disease status. Conclusion: The overall factor structure of the Finnish version was consistent with that of the reference standard, and it can be designated as the official version of the UDysRS for Finnish speaking populations.

1.
Chaudhuri
KR
,
Jenner
P
,
Antonini
A
.
Should there be less emphasis on levodopa-induced dyskinesia in Parkinson’s disease?
Mov Disord
.
2019 Jun
;
34
(
6
):
816
9
. .
2.
Cenci
MA
,
Riggare
S
,
Pahwa
R
,
Eidelberg
D
,
Hauser
RA
.
Dyskinesia matters
.
Mov Disord
.
2020 Dec
;
35
(
3
):
392
6
. .
3.
Goetz
CG
,
Nutt
JG
,
Stebbins
GT
.
The unified dyskinesia rating scale: presentation and clinimetric profile
.
Mov Disord
.
2008 Dec
;
23
(
16
):
2398
403
.
4.
Goetz
CG
,
Stebbins
GT
,
Theeuwes
A
,
Stocchi
F
,
Ferreira
JJ
,
van de Witte
S
,
Temporal stability of the unified dyskinesia rating scale
.
Mov Disord
.
2011 Dec
;
26
(
14
):
2556
9
.
5.
Eberhard
DM
,
Simons
GF
,
Fennig
CD
.
Ethnologue: languages of the world
. 23rd ed.
Dallas, TX
:
SIL International
;
2020
.
6.
Brown
T
.
Confirmatory factor analysis for applied research
.
New York, NY
:
The Guildford Press
;
2006
.
7.
Cubo
E
,
Goetz
CG
,
Stebbins
GT
,
LaPelle
NR
,
Tilley
BC
,
Wang
L
,
Independent spanish validation of the unified dyskinesia rating scale
.
Mov Disord Clin Pract
.
2014 Sep
;
1
(
3
):
213
8
. .
8.
Fowler
F
.
Improving survey questions: design and evaluation
.
Thousand Oaks, CA
:
Sage Publications
;
1995
.
9.
Muthen
LK
,
Muthen
BO
.
Mplus user’s guide
. 6th ed.
Los Angeles, CA
:
Muthen & Muthen
;
2010
.
10.
Gorsuch
RL
.
Factor analysis
. 2nd ed.
Hillsdale, NJ
:
Lawrence Erlbaum Associations, Inc.
;
1983
.
11.
Lappalainen
T
,
Koivumäki
S
,
Salmela
E
,
Huoponen
K
,
Sistonen
P
,
Savontaus
ML
,
Regional differences among the Finns: a Y-chromosomal perspective
.
Gene
.
2006 Jul
;
376
(
2
):
207
15
.
12.
Sistonen
J
,
Fuselli
S
,
Palo
JU
,
Chauhan
N
,
Padh
H
,
Sajantila
A
.
Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales
.
Pharmacogenet Genomics
.
2009 Feb
;
19
(
2
):
170
9
. .
13.
Pietarinen
P
,
Tornio
A
,
Niemi
M
.
High frequency of CYP2D6 ultrarapid metabolizer genotype in the finnish population
.
Basic Clin Pharmacol Toxicol
.
2016 Sep
;
119
(
3
):
291
6
.
14.
Ortiz
R
,
Scheperjans
F
,
Mertsalmi
T
,
Pekkonen
E
.
The prevalence of adult-onset isolated dystonia in Finland 2007–2016
.
PLoS One
.
2018 Nov
;
13
(
11
):
e0207729
.
15.
Sipilä
JO
,
Hietala
M
,
Siitonen
A
,
Päivärinta
M
,
Majamaa
K
.
Epidemiology of Huntington’s disease in Finland
.
Parkinsonism Relat Disord
.
2015 Jan
;
21
(
1
):
46
9
.
16.
GBD 2015 Neurological Disorders Collaborator Group
.
Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the global burden of disease study 2015
.
Lancet Neurol
.
2017 Nov
;
16
(
11
):
877
97
.
17.
Havulinna
AS
,
Tienari
PJ
,
Marttila
RJ
,
Martikainen
KK
,
Eriksson
JG
,
Taskinen
O
,
Geographical variation of medicated parkinsonism in Finland during 1995 to 2000
.
Mov Disord
.
2008 May
;
23
(
7
):
1024
31
.
18.
Isotalo
J
,
Vahlberg
T
,
Kaasinen
V
.
Unchanged long-term rural-to-urban incidence ratio of Parkinson’s disease
.
Mov Disord
.
2017 Nov
;
32
(
3
):
474
5
. .
19.
Faust-Socher
A
,
Anis
S
,
Kestenbaum
M
,
Shabtai
H
,
Taichman
T
,
Bar David
A
,
Validation of the hebrew version of the unified dyskinesia rating scale
.
Neuroepidemiology
.
2020 Jun
;
54
(
4
):
356
62
.
20.
Akbostanci
MC
,
Bayram
E
,
Yilmaz
V
,
Rzayev
S
,
Özkan
S
,
Tokcaer
AB
,
Turkish standardization of movement disorders society unified Parkinson’s disease rating scale and unified dyskinesia rating scale
.
Mov Disord Clin Pract
.
2018 Jan–Feb
;
5
(
1
):
54
9
. .
21.
Horváth
K
,
Aschermann
Z
,
Ács
P
,
Bosnyák
E
,
Deli
G
,
Pál
E
,
Validation of the hungarian unified dyskinesia rating scale
.
Ideggyogy Sz
.
2015 May
;
68
(
5–6
):
183
8
.
22.
Skorvanek
M
,
Minar
M
,
Grofik
M
,
Kracunova
K
,
Han
V
,
Cibulcik
F
,
Validation of the official Slovak version of the unified dyskinesia rating scale (UDysRS)
.
Parkinsons Dis
.
2015 Jul2015
;
2015
:
674796
. .
23.
Biundo
R
,
Weis
L
,
Abbruzzese
G
,
Calandra-Buonaura
G
,
Cortelli
P
,
Jori
MC
,
Impulse control disorders in advanced Parkinson’s disease with dyskinesia: the ALTHEA study
.
Mov Disord
.
2017 Nov
;
32
(
11
):
1557
65
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.